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Abstract
Regulator of G protein signaling 9–2 (RGS9–2) is a protein that is highly enriched in the striatum, a brain region that
mediates motivation, movement and reward responses. We identified a naturally occurring 5 nucleotide deletion
polymorphism in the human RGS9 gene and found that the mean body mass index (BMI) of individuals with the deletion
was significantly higher than those without. A splicing reporter minigene assay demonstrated that the deletion had the
potential to significantly decrease the levels of correctly spliced RGS9 gene product. We measured the weights of rats after
virally transduced overexpression of RGS9–2 or the structurally related RGS proteins, RGS7, or RGS11, in the nucleus
accumbens (NAc) and observed a reduction in body weight after overexpression of RGS9–2 but not RGS7 or 11. Conversely,
we found that the RGS9 knockout mice were heavier than their wild-type littermates and had significantly higher
percentages of abdominal fat. The constituent adipocytes were found to have a mean cross-sectional area that was more
than double that of corresponding cells from wild-type mice. However, food intake and locomotion were not significantly
different between the two strains. These studies with humans, rats and mice implicate RGS9–2 as a factor in regulating body
weight.
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Introduction
A large body of data indicates that brain circuits in the striatum
that utilize opioid peptides and dopamine as neurotransmitters are
important in i) the motivation to acquire food, ii) encoding food
value and reward and iii) the orchestration of movements for
acquiring food [1,2].
Regulators of G-protein signaling (RGS) are a family of proteins
that can accelerate GTP hydrolysis catalyzed by G protein
coupled receptor (GPCR)-activated, Ga G protein subunits.
Consequently, they accelerate the termination of GPCR signals
[3]. In addition to the class-defining RGS domain which is
responsible for the GTPase accelerating function (GAP) function,
RGS proteins also contain additional regions that mediate
intracellular interactions and non-canonical functions that are
distinct from the canonical GAP function [4].
This study which investigates the role of the striatally enriched
RGS protein, RGS9–2 [5], in regulating body weight was
prompted by the following findings. First, RGS9–2 specifically
modulates the GPCRs, D2-like dopamine receptors (D2R)
[6,7,8,9], and mu opioid receptors [10,11,12]. Second, D2R and
mu opioid receptor signaling in the striatum regulates feeding
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27984behavior, body weight [1,2], and reward responses [13,14]. Third,
several studies have shown that altered RGS9–2 levels modulate
the reward responses to drugs that activate brain opioid and
dopamine receptors [15].
RGS9–1 and RGS9–2 are the short and long splice variants,
respectively, of the RGS9 gene and the expression of each of these
variants is highly tissue specific. RGS9–2 is expressed specifically
in the brain and is highly enriched in striatum neurons while
RGS9-1is thought to be expressed specifically in the retina
[5,16,17]. RGS9–1 and 2 are members of the R7 RGS protein
subfamily [18] whose members are defined by the presence of two
N-terminal domains: i) a DEP (for dishevelled/EGL-10/pleckstrin
homology) domain and ii) Gc-like domain (GGL) that binds Gb5,
an outlying member of the G protein beta subunit family.
Here,we identifyapolymorphisminthe humanRGS9genelikely
to alter functional levels of RGS9–2. Based on our observations that
RGS9knockoutmicewereheavierthantheirwild-typelittermateswe
asked if this human RGS9 gene polymorphism was associated with
altered body mass index. We also tested the effects of virally-
mediated overexpression of RGS9–2 in the rat nucleus accumbens
(NAc) on body weight. The results from these experiments, involving
humans, rats and mice, suggest that alterations in functional levels of
RGS9–2 can affect body weight.
Results
Humans with a naturally occurring intronic deletion in
the RGS9 gene have significantly higher body mass index
(BMI)
We identified a naturally occurring deletion polymorphism
(denoted here as DTTTCT) in intron 13 of the human RGS9 gene.
This human RGS9 gene polymorphism has been reported
previously as rs3215227 in the Single Nucleotide Polymorphism
database, (dbSNP, http://www.ncbi.nlm.nih.gov/snp), and
matched perfectly to a recently defined binding motif [19] for
the ubiquitously expressed RNA binding protein, polypyrimidine
tract binding protein (PTB). PTB was originally identified as a
protein with an important role in RNA splicing [20], and is now
known to function in a large number of diverse cellular processes
including polyadenylation, mRNA stability and translation
initiation.
Removal of introns from RNA transcripts and the splicing of
flanking exons to produce the mature mRNA occur via the
coordinated recognition of important sequence elements within
the RNA transcript by an RNA-protein complex known as the
spliceosome. Important sequence elements within the RNA
transcript that direct the splicing of the transcript include the
branch point, the 59 splice site, the polypyrimidine tract, and the
39 splice site. These sequence elements also serve as binding sites
for additional factors such as PTB that modulate the splicing of
specific transcripts [20].
The RGS9 deletion polymorphism, DTTTCT, lies within a
polypyrimidine tract, 72 nucleotides upstream of exon 14 and
only 3 bases away from the branch point. The location of the
DTTTCT polymorphism and coincidence with a PTB binding motif
suggested that the presence of the deletion could alter processing of
RGS9 transcripts and have important functional consequences:
exons 13 and 14, that flank the DTTTCT deletion, code for the
conserved RGS domain that mediates GTPase accelerating
protein (GAP) function [3,17,18]. Hence, incorrect splicing of
these exons will result in protein products that lack a functional
RGS domain.
Since, i) the DTTTCT deletion polymorphism had the potential
to reduce the functional levels of RGS9 protein and ii) our
preliminary results indicated that RGS9 knockout mice were
heavier than their wild-type littermates, we hypothesized that
humans with the DTTTCT polymorphism were on average heavier
than those who were negative for the polymorphism.
A preliminary screen indicated that the DTTTCT deletion
polymorphism was rare in Caucasians and African Americans,
occurring at a frequency of less than 1%. As a result of the
infrequency of the deletion in these ethnic groups we estimated
that we would not be able identify enough DTTTCT deletion
positive Caucasians or African Americans to test for an association
between the DTTTCT polymorphism and body weight.
However, our preliminary screen suggested that DTTTCT was
more common in East Asians occurring at significantly higher
frequencies. Therefore this ethnic group was studied to test for a
relationship between the DTTTCT deletion and body weight. We
genotyped 491 individuals of Chinese, Filipino, Japanese, Korean,
Pacific Islander, or Southeast Asian ancestry from whom blood
samples had previously been obtained along with height, weight,
age and sex data.
Forty nine individuals were homozygous for the DTTTCT
deletion (DTTTCT+/+), 197 individuals were heterozygous for the
deletion (DTTTCT+/-), and 245 individuals tested negative for the
deletion (DTTTCT-/-). The mean body mass index (BMI) was 25
(SD=4.5) for the group homozygous for the deletion and 24.9
(SD=4.4) for individuals heterozygous for the deletion. The mean
BMI of the 245 individuals that tested negative for the deletion
(DTTTCT-/-) was 24.2 (SD=4.1) and was significantly different
(t=1.99, p,0.05), from the mean BMI, 24.9 (SD=4.4), of the 246
individuals that tested positive for the deletion (DTTTCT+ve, i.e.
individuals either homozygous, DTTTCT+/+, or heterozygous,
DTTTCT+/-, for the deletion.
Table 1 outlines the ethnic sub-composition of the East Asian
population sample, the frequency of the occurrence of the deletion
in each sub-group and the mean BMIs of the DTTTCT+ve and
Table 1. Table outlining the body mass index (BMI)
associated with each ethnic group and with DTTTCT deletion
positive (D+) and DTTTCT (D-) deletion negative groups.
BMI(Mean±SD) (No. of Subjects)
Ethnicity D+ D- D+ & D-
Chinese (45.0%)
a 24.464.6 (113)
b 23.263.5 (108)
b {23.864.1 (221)
b
Japanese (15.9%)
a 25.165.6 (31)
b 24.464.2 (47)
b 24.664.8 (78)
b
Korean (4.7%)
a 24.363.6 (4)
b 23.864.1 (19)
b 123.964.0 (23)
b
Pacific Islander
(21.0%)
a
25.963.9 (61)
b 25.764.2 (42)
b 25.864.0 (103
b
Southeast Asian
(13.4%)
a
25.163.3 (37)
b 25.365.0 (29)
b 25.264.1 (66)
b
All East Asians
(100%)
a
#24.964.4 (246)
b 24.264.1 (245)
b 24.664.2 (491)
b
Table Key:
D+: DTTTCT deletion positive; D-: DTTTCT deletion negative
aPercentages in parenthesis in the first column indicate percent fraction of the
study population that belong to each ethnic group.
bNumbers in parenthesis in columns 2–4 indicate the number of subjects
associated with each cell.
{, 1Ethnic groups have significantly different BMI’s (ANOVA, F=4.71, P,0.005);
follow-up Fisher’s Least Significant Difference test (P,0.05) test shows
{Chinese have lower BMI than Southeast Asians or Pacific Islanders and
1Koreans having a lower BMI than Pacific Islanders.
#Student independent t-test shows significant difference (p,0.05) between
DTTTCT deletion positive (D+)a n dDTTTCT deletion negative (D-) individuals.
doi:10.1371/journal.pone.0027984.t001
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incidence of the deletion was significantly different (x
2=16,
p,0.005) between some of the different ethnic groups examined:
those having Japanese and Korean ancestry had the lowest
frequency of occurrence of DTTTCT.
Analysis of variance of the relationship of ethnicity among the
East Asian subjects on body mass index shows significant
differences between those identifying themselves as Chinese,
Japanese, Korean, Pacific Islander, or Southeast Asian. The
different East Asian ethnic groups have significantly different
BMI’s (ANOVA, P,0.005); follow-up Fisher’s Least Significant
Difference test (P,0.05) test shows that Chinese have lower BMI
than Southeast Asians or Pacific Islanders and Koreans have a
lower BMI than Pacific Islanders. However, we found that within
each ethnic group, the differences in the BMI between deletion-
positive and deletion-negative individuals were not significant.
Men had a significantly higher (t=6.56, p,0.001) BMI than
women (25.863.6 versus 23.464.5, Mean6SD, Table 2), but, as
would be expected by the chromosome 17 location of the RGS9
gene, there was no association (x
2=0.74) between sex and
presence of the deletion and the deletion is similarly distributed
in men and women. Therefore, unequal gender distribution
between the deletion positive and negative groups does not
account for the difference in BMI between the two groups. Finally,
there was no relationship between BMI and age in our study
population.
A more detailed description of the East Asian study subjects are
provided in the Supporting Information Tables S1 and S2.
Effects of the DTTTCT deletion polymorphism on splicing
of minigene construct
Since the DTTTCT deletion was close to the branch point for
RNA splicing and corresponded to a binding motif for PTB, we
attempted to determine if the deletion could alter splicing of the
RGS9 gene transcript.
Analysis of RNA from the tissue of individuals with the
DTTTCT polymorphism would be the ideal method of assessing
the effect of this deletion on splicing. However, RNA extracted
from tissues of DTTTCT+ve individuals was not available to us. In
addition, the splicing of the RGS9 transcript is highly tissue
specific. For example, in humans, the shorter alternatively spliced
form, RGS9-1 is highly expressed in the retina but not detectable
in the brain, while RGS9-2 is largely expressed in the brain [17]
and not detectable in the retina. Therefore it is not certain that
the effect of DTTTCT on splicing of RGS9 RNA in an accessible
tissue such as blood would be reflective of the splicing in the
tissues responsible for the increased BMI phenotype. Further-
more, the RGS9 gene transcript is very large (.170 kilobases) [17]
and splicing alterations observed in vivo for such large transcripts
cannot be definitively linked to a particular gene variation
without sequencing the entire gene sequence for all the
individuals in the study sample. In practice, such extensive
sequencing was not possible and therefore we would not
definitively exclude the possibility that the altered splicing arose,
instead, from alternative undiscovered variations in non-
sequenced sections of the gene.
To circumvent such constraints splicing reporter minigene
assays are often used to assess the impact of allelic variants on
splicing [21,22]. These assays examine the splicing of a minigene
reporter constructed using the portion of the gene containing the
variation and allow for a more definitive linkage of the gene
variation to splicing alterations. As described in Methods and
Materials and depicted schematically in Fig. 1A, an RGS9 gene
fragment containing exon 13 and intron 13 was utilized to
construct a splicing reporter minigene which was transfected into
HEK293 cells. The resulting gene transcripts were analyzed by
reverse transcriptase PCR (RT-PCR) and gene sequencing.
Incorporation of DTTTCT deletion into the RGS9 minigene
fragment increased the frequency of exon skipping during splicing
of the minigene transcript and decreased the fraction of the
correctly spliced transcript (i.e. transcript containing all 4 minigene
exons, Fig. 1B & C).
Deletion of the RGS9 gene produces heavier mice
The weight disparity between the RGS9 knockout (rgs9-/-) and
wild-type (rgs9+/+) littermates is readily apparent by visual
inspection – RGS9 knockout mice are heavier (Fig. 2A).
To quantify the development of this phenotype, we recorded the
weight of wild-type and homozygous RGS9 knockout (rgs9-/-) mice
born from heterozygote breeders that were given ad libitum access
to water and 4% fat rodent chow. Mice were weighed daily from
weaning until post-weaning day 55 (postnatal days 21 through 76).
The weights of both male and female rgs9-/- diverged from their
wild-type littermates, at approximately 19 g for females and 21 g
for males, and this disparity increased through day 50 post-
weaning (Fig. 2B and C). Though we did not systematically
measure body weight past day 55, observation of older animals,
indicated that the increased weight of RGS9 knockout animals
persisted at least through 12 months of age.
A measurement of the food consumed indicated that the
altered weight of the knockout mice was not due to increased
food intake. The amounts of food consumed by the rgs9-/- and
rgs9+/+ were similar: 3.2260.29 and 3.0760.29 g/day (Mean6
SEM) for the wild-type mice and the RGS9 knockout mice,
respectively.
The locomotor activity of the wild-type and RGS9 knockout
male and female mice measured over a 2 hr time period was
similar (Fig. 2D). At an earlier time point (30 min) the male rgs9-/-
mice demonstrated a small but significantly increased ambulatory
activity when compared to their wild-type counterparts. This small
increase in initial activity could represent an increased anxiety
phenotype for these mice, but cannot easily explain their increased
weight.
Table 2. Table outlining the mean body mass index (BMI)
associated with males and females and with DTTTCT deletion
positive (D+) and DTTTCT (D-) deletion negative male and
female subjects.
BMI (Mean±SD) (No. of Subjects)
SEX D+ D- D+ & D-
Females (51.7%)
a 23.964.8 (122)
b 22.964.0 (132)
b 23.464.5 (254)
b
Males (48.3%)
a 2663.7 (124)
b 25.663.6 (113)
b {25.863.6 (237)
b
All Subjects
#24.964.4 (246)
b 24.264.1 (245)
b 24.664.2 (491)
b
Table Key:
D+: DTTTCT deletion positive; D-: DTTTCT deletion negative
aPercentages in parenthesis in the first column indicate percent fraction of the
study population that is either female or male.
bNumbers in parenthesis in columns 2–4 indicate the number of subjects
associated with each cell.
{Men had a significantly higher (Student independent t-test, t=6.56, p,0.001)
BMI than women.
#Student independent t-test shows significant difference (p,0.05) between
DTTTCT deletion positive (D+)a n dDTTTCT deletion negative (D-) individuals.
doi:10.1371/journal.pone.0027984.t002
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and undetectable levels of RGS9 protein expression in
visceral fat depots of wild-type mice
We dissected visceral white adipose tissue from mesenteric,
epididymal and perirenal depots from age-matched wild-type and
RGS9 knockout male mice between 2 and 4 months old and found
significantly larger amounts of visceral adipose tissue in the RGS9
knockout mice (Fig. 3A).
The epididymal adipose tissue from 8 week old male or female
wild-type mice was Western blotted and probed with a validated
antibody previously shown to recognize both the long and short
RGS9 isoforms [23]. While RGS9-2 protein expression was clearly
detected in striatal tissue, we were unable to detect any RGS9
protein signal in the visceral fat from the same mouse using this
approach (Fig. 3B). We also further validated the antibody by
confirming that no protein signal was detected when Western blots
of striatal tissue from the rgs9-/- mice were probed with the
antibody (data not shown).
An analysis of the epididymal (Fig. 3C, D and E) or mesenteric
depots showed that the adipocytes from RGS9 knockout animals
were significantly enlarged when compared to the wild-type
animals (Fig. 3D and E).
RGS9-2 over-expression in rat nucleus accumbens (NAc)
leads to weight loss
Following our observations of the increased weight of RGS9
knockout mice, we tested whether overexpression of RGS9-2 in
the NAc could produce weight loss. We used a previously validated
Herpes Simplex Virus (HSV) delivery system to drive overexpres-
sion of RGS9-2 in the nucleus accumbens (NAc) shell of male rats
[7,24] while quantifying their body weight dynamics. The effects
of RGS protein overexpression on body weight were compared
with the effects of control LacZ expression.
Rats injected with the HSV RGS9-2 construct exhibited
enhanced weight-loss relative to the LacZ controls. The loss in
weight of the HSV RGS9-2 injected rats relative LacZ was
Figure 1. Effect of RGS9 gene elements containing the DTTTCT deletion on the splicing of a minigene reporter construct. (A) Schematic
representation of the minigene reporter system used to assess the effect of the intron 13 TTTCT deletion (represented as D) on RGS9 gene splicing. A
section of the RGS9 gene spanning the 39 end of exon 13 (gray shaded box) and intron 13 (gray dashed line between Exon 2 and 3) was inserted at
the indicated restriction enzyme sites. Note that the 39 end of the RGS9 gene exon 13 (gray shaded box) forms the 39 end of Exon 2 of the new
minigene construct. In subsequent panels ‘‘DTTTCT+ve’’ refers to the minigene construct made by inserting the RGS9 gene fragment with the TTTCT
deletion while ‘‘DTTTCT-ve’’ refers to a minigene construct that is identical to DTTTCT except that it does not have the TTTCT deletion. (B) The DTTTCT-ve
and DTTTCT+ve RGS9 gene fragment-containing minigenes were transfected separately into HEK293 cells. The minigene transcripts were visualized by
reverse transcription, PCR amplification followed by agarose gel electrophoresis. The gel image (left) is a representative image of DNA bands
produced from the separate minigene transcripts that are depicted schematically on the right (labeled ‘‘a’’ and ‘‘b’’, respectively). The binding sites of
the PCR primers used to amplify ‘‘a’’ and ‘‘b’’ are indicated by the forward and reverse arrows in A. We sequenced bands ‘‘a’’ and ‘‘b’’ to determine
that they are derived, respectively, from the minigene products shown schematically to the right of the gel image. (C) Densitometric quantification of
the relative intensities of bands ‘‘a’’ and ‘‘b’’, (*p,0.01, t test).
doi:10.1371/journal.pone.0027984.g001
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of initial body mass).
It has been shown previously that HSV-transduced RGS9-2
protein expression in the rat NAc peaks on day 3–4 post-injection
and rapidly declines thereafter [7]. The relative weight loss
experienced by the HSV-RGS9-2 injected rats was similarly
transient: on post-surgical day 5, the body weights of the RGS9-2
expressing animals were no longer significantly different from the
LacZ overexpressing controls. By day 15 following viral injection,
group weights were indistinguishable (Fig. 4).
In contrast, overexpression of the structurally similar proteins,
RGS7 and RGS11, in rat NAc shell led to weight gain relative to
LacZ overexpression (Fig. 4). For example, on day 3 post-surgery,
RGS11 overexpressing rats weighed on average 10.8 g (3.6% of
total body mass) more than the LacZ controls.
Discussion
In this manuscript we provide data from human, mouse and rat
studies that suggest that RGS9-2, a brain specific RGS family
member, can regulate body weight and adiposity. First we link an
intronic deletion in the RGS9 gene to increased body mass index
in humans (BMI). We provide mechanistic insights into this
association by showing i) that the intronic deletion is coincident
with a binding motif for the polypyrimidine tract binding protein
(PTB), a protein involved in regulating the processing of RNA and
ii) that the intronic variation can alter the splicing of the RGS9
gene product. Further confirmation for a role of RGS9 in
regulating body weight is provided by observations showing that
RGS9 knockout mice are heavier than their wild-type littermates,
have increased adiposity and adipocytes with approximately
doubled cross-sectional area. Finally we identify a possible site
for the action of RGS9-2 in regulating body-weight by showing
that overexpression of RGS9-2 in the nucleus accumbens of rats
can decrease body-weight.
A major finding of our study is that an intronic deletion
polymorphism in the RGS9 gene (DTTTCT) is associated with
significantly increased body mass index (BMI) in humans. The
increase in mean BMI (24.9 versus 24.2) represents an increase in
weight from 68.2 kg (150 lb) to 70 kg (154 lb), or a 2.7% increase
in weight, for an individual 168 cm (5 ft 6 inch) tall. Thus, the
influence of the DTTTCT deletion polymorphism on body weight is
quite mild: a World Health Organization panel has suggested that
the obesity cut-off definition for Asians should be lowered to a
BMI of 25 [25], compared to 35 for Caucasians, but the mean
BMI of the DTTTCT deletion positive East Asian individuals in our
study is less than even this lowered BMI value.
An examination of Table 1 shows that the increase in mean
BMI of the DTTTCT deletion positive subjects relative to the
deletion negative individuals is greatest among the Chinese, is very
small in Pacific Islanders and is reversed in Southeast Asians.
However, the above differences and the differences in BMI
between deletion positive and negative individuals within each
ethnic sub-group were not statistically significant. Nevertheless, it
Figure 2. Body weight and locomotor activity comparisons of RGS9 wild-type (rgs9+/+) and RGS9 knockout mice (rgs9-/-). (A)1 2w k
old male rgs9-/- (on right) with wild-type, rgs9+/+ littermate at left. (B) Comparison of weight of female rgs9-/- and rgs9+/+ littermates from weaning
through day 50 post-weaning (number of mice at day 50, rgs9+/+ 9, rgs9-/- 6). (C) Comparison as in B with male mice (number of mice, rgs9+/+ 11,
rgs9-/- 8). Points represent mean6SEM. Solid line, p,0.005, repeated measures ANOVA. (D) Comparison of ambulatory locomotor activity of 8 week
old male and female rgs9-/- (black bars) and rgs9+/+ (open bars) mice, after placement of mice in activity measurement chambers over a 2 hr period.
Bars represent mean6SEM number of beam breaks per mouse after 30 min and after 2 hr (number of male mice, rgs9+/+ 8, rgs9-/- 8, number of
female mice, rgs9+/+ 8, rgs9-/- 8, *p,0.02, unpaired t test male mice, rgs9+/+ compared to rgs9-/-).
doi:10.1371/journal.pone.0027984.g002
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descendants of voyagers from Southeast Asia—either Taiwanese
aborigines or former inhabitants of New Guinea and the
surrounding islands [26,27], they are more closely related
genetically to Southeast Asians than to Chinese, Japanese or
Koreans. Hence, it is possible that within these two former
genetically similar ethnic groups, the DTTTCT deletion is not
correlated to BMI, or the effect of the deletion is masked by other
factors. Future studies with larger samples sizes will be required to
determine whether the effect of DTTTCT deletion on BMI is
restricted to a subset of ethnic groups.
The association between the DTTTCT intronic deletion poly-
morphism in the RGS9 gene and increased BMI was studied in
the East Asian population because the deletion was rare in other
groups. However, these results do not imply that RGS9-2
contributes to body weight set-points only in this ethnic group.
Other RGS9-related variations, including yet unidentified varia-
tions in the RGS9 gene and regulatory regions, may contribute to
variations in cellular levels of RGS9-2 protein and thus modify
body-weight in individuals regardless of ethnicity.
It is also interesting to note that the mean weights of the female
wild-type and knockout mice diverged significantly from each
other at an earlier time point than for the male mice (day 30 after
weaning for the females versus day 40 after weaning for the males).
In addition, close to the end of the experiment, on day 50, the
mean percent increase in weight of the female knockout mice
compared to the female wild-type mice was 16.5% while the mean
percent increase for the male knockout mice relative to the wild-
type mice was 6.8%, but this difference was not statistically
significant. Similarly, the difference in mean BMI of the DTTTCT
deletion positive relative to the deletion negative East Asian
individuals was greater in females than in males (Table 2) and the
difference between the genotypes was marginally significant in
females but not in males (p=0.07 for females versus p=0.45 for
males, t test). Future studies with larger samples sizes will be
required to determine whether the effect of RGS9 gene variations
on weight is more prominent in females.
The location of the DTTTCT deletion polymorphism and the
identity to a binding motif for the polypyrimidine tract binding
protein (PTB) suggested that this naturally occurring allele could
affect the splicing of RGS9 mRNA. Indeed, our data shows that
the deletion can alter splicing and produces a substantial reduction
in correctly-spliced RGS9 gene transcript (Fig. 1). The DTTTCT
polymorphism lies within intron 13. The exons that flank intron 13
code Exons 13 and 14 which encode the RGS domain [17]. The
RGS domain is conserved among all the RGS family members
and mediates the canonical Ga GTPase accelerating (GAP)
function [3]. Thus, altered splicing due to the DTTTCT deletion
polymorphism, such as exon skipping or intron retention, will
result in a protein product that is truncated at this region and
therefore lacks the important class-defining GAP function. These
Figure 3. Comparison of visceral fat and mesenteric adipocytes
fromRGS9 wild-type (rgs9+/+) and RGS9 knockout mice (rgs9-/-).
(A) Combined weight of epididymal and mesenteric fat depots
expressed as a percentage of body weight. (number of mice, rgs9+/+
5, rgs9-/- 6,*p,0.02, t test). (B) Western blot (WB) of visceral fat (Fat) and
striatal (Str.) tissue from an 8 week old female wild-type mouse probed
with an antibody directed against RGS9. Numbers to the left of the blot
indicate position of the 75 kDa and 50 kDa protein molecular weight
markers. The blot is representative of experiments performed with 2
female and 2 male mice. (C) representative images of epididymal
adipocytes from rgs9+/+ (left panel) and rgs9-/- (right panel) mice. Scale
bar represents 50 mm. (D) Apparent area of adipocytes observed in
hematoxylin and eosin stained epididymal fat sections. n, rgs9+/+ 463
cells, rgs9-/- 497 cells pooled from sections from two separate animals
each, (*p,0.01, t test). (E) Cumulative frequency distribution of
apparent epididymal adipocyte cross-sectional area. Adipocyte cross-
sectional area is plotted on the x-axis, and y-axis indicates the percent
of total cells with cross-sectional area less than the value indicated on
the x-axis.
doi:10.1371/journal.pone.0027984.g003
Figure 4. Body-weight changes in rats following Herpes
simplex virus (HSV)-mediated over-expression of RGS proteins
in the nucleus accumbens shell. Graphs depict the difference in
body weight following intracranial injection of HSV constructs encoding
RGS7 (open circles), RGS9-2 (filled squares) and RGS11 (closed triangles)
into the nucleus accumbens (day 0), relative to the weight of control
group HSV-LacZ-injected rats. The weights at day 0 for each of the
paired comparisons were as follows: LacZ, 281.764.4 (n=18); RGS7,
283.362.7 (n=20); LacZ, 289.763.6 (n=51); RGS9-2, 290.264.26
(n=48); LacZ, 287.563.2 (n=19); RGS11 292.263.4 (n=22). Not all
the animals were followed until day 15, hence ‘‘n’’s at day 15 were as
follows: LacZ, 22; RGS9-2, 14; RGS11, 11. *p,0.05, **p,0.01, repeated
measures ANOVA followed by Fisher’s least squares test.
doi:10.1371/journal.pone.0027984.g004
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polymorphism have a higher BMI due to a reduction in the
functional levels of brain RGS9-2.
Support for the suggestion that RGS9-2 is important in
regulating body-weight is provided by the finding that mice with
the RGS9 gene deletion have elevated body weight (Fig. 2) and that
conversely overexpressing RGS9-2 in the rat nucleus accumbens
(NAc), via herpes simplex virus (HSV)-mediated gene transduc-
tion, lowers body weight relative to control animals (Fig. 4). RGS9-
2 is expressed in the vast majority of striatal medium spiny neurons
[7], which comprise 90–95% of the neurons in the striatum [28].
Hence, the percentage of infected non-target cells that do not
normally express RGS9-2 is small and consequently, this
technique has been successfully utilized to define physiological
and pathophysiological functions for RGS9-2 using both rodent
and primate models [7,24].
Indeed, the results presented above mirror those from previous
studies, where HSV-mediated RGS9-2 over-expression in the rat
striatum has been shown to produce functional responses that are
opposite to those exhibited by the RGS9 knockout mice. For
example, RGS9 knockout mice exhibit increased cocaine-induced
locomotion, while HSV-mediated overexpression of RGS9-2 in
rats dampens cocaine-induced locomotion [7]. In addition, RGS9
knockout mice show accelerated development of drug-induced
dyskinesia [6], while HSV-mediated overexpression of RGS9-2 in
the striatum of rats and monkeys diminished intensity of drug-
induced dyskinesia [24].
The specificity of RGS9-2 overexpression effects are highlighted
by the parallel experiments with RGS7 and RGS11 [18], closely
related members of the R7 RGS protein family. Though RGS11 is
thoughttobe specificallyexpressed inretinal bipolarneuron,thetwo
proteins have been shown in vitro to act as GTPase accelerating
proteins for the same G proteins [18,29,30]. The opposite effects of
RGS9-2andRGS7andRGS11overexpressiononbodyweight(Fig.
4) suggest that the effects cannot be attributed solely to the GAP
function which is common to the three proteins. While we do not yet
understand the mechanism for the opposing action of these proteins
on body weight, it is interesting to note that R7 RGS proteins, such
asRGS7, RGS9andRGS11, can compete fortheir obligatebinding
partners (Gb5 and R9AP or R7BP). In fact, knock-out of these
binding partners leads to marked reduction in all R7 RGS proteins
[31,32,33]. Therefore, one hypothesis explaining the relative
increase in weight produced by RGS7 or RGS11 overexpression,
is that RGS7 and RGS11 competes with RGS9-2 for the available
Gb5 and R7BP, destabilizing native RGS9-2 protein and producing
an effect on weight similar to that seen in RGS9 knock-out mice.
Results similar to those we report have been observed at the cellular
level: previous studies have reported that, despite their structural
similarity, RGS7 and RGS11 produce opposite effects to those
produced by RGS9 on cellular signaling pathways [34,35].
While there is one report of RGS9 transcript expression in
blood lymphocytes [36], all other studies examining the tissue
distribution and function of RGS9 gene products have reported
only on the expression of RGS9 in the brain and the retina
[5,17,37,38]. Thus, the absence of reports of RGS9 expression in
peripheral tissue, interpreted in conjunction with, i) our observa-
tions with rats demonstrating that RGS9-2 overexpression in the
NAc lowers body weight compared to control animals (Fig. 4) and
ii) undetectable levels of RGS9 protein expression in fat tissue (Fig.
3B), suggest that the RGS9 acts to regulate body-weight and
adiposity via expression in the brain.
RGS9-2 exhibits extremely dense expression in rodent striatum,
and pleasure, desire and reward circuits operating in the striatum
are thought to be important in obesity and eating disorders [39].
However, the actions of RGS9-2 in regulating body-weight and
adiposity are likely to involve alternative striatal connections, since
we report that the food intake of the heavier RGS9 knockout mice
was similar to that of wild-type mice.
The dopamine-sensitive NAc reward centers are densely inter-
connected with the hypothalamus, a brain region that is critical for
regulating energy expenditure. Hypothalamic neurons, including
orexin [40,41] and melanin concentrating hormone neurons [42],
make connections with the NAc, and the NAc can influence
hypothalamic functions [43]. Thus, RGS9-2 via expression in the
NAc could modulate the activity of hypothalamic centers that
controlenergy expenditure and future experiments will examine the
total and resting oxygen consumption in the RGS9 knockout mice.
Interestingly, in addition to extremely dense expression in striatum,
RGS9-2 is also localized to medial hypothalamus [38]. However, it
is clear from our experiments that modulating RGS9-2 levels
specifically in the NAc can alter body weight (Fig. 4).
Human genetic studies have linked variations in two other R7
RGS proteins, RGS6 [44] and RGS7 [44] to obesity. The above
human genetic studies provide a precedent for R7 RGS family
proteins regulating body-weight through their expression in the
brain since these proteins have been reliably detected only in the
brain or in excitable tissue such as retina and heart [37,45,46].
More recently, it has been reported that mice with a targeted
deletion of one copy of the G protein Gb5 subunit gene are
heavier and have increased adiposity when compared to their
wild-type counterparts, even though their food intake was not
different and their locomotor activity levels were enhanced [47].
Similarly, we found that the food intake of the heavier RGS9
knockout mice was not different from their wild-type littermates,
and also observed a small but significant increase in initial activity
of the male RGS9 knockout mice when placed in the movement
measurement cages (Fig. 2D). Gb5 protects R7 RGS family
proteins from proteolysis and expression of R7 RGS family
proteins, including RGS9, is eliminated or hugely reduced in the
absence of Gb5 [18,32]. Therefore our results raise the possibility
that the increased adiposity and weight phenotype of heterozygous
Gb5 knockout mice is produced as a result of a Gb5 knockdown-
mediated reduction in brain RGS9-2 protein levels.
Human and mouse studies have also implicated RGS2, 4 and 5,
in the regulation of body weight and obesity [48,49,50,51].
However these RGS proteins and RGS9 likely regulate body
weight through different mechanisms: RGS2, 4 and 5 are
members of a different R4 subfamily of RGS proteins, have a
different molecular architecture and strikingly different cellular
and tissue expression patterns compared to RGS9 [18,37,52]. It
has been reported that knock-in mice homozygous for a mutant
Gai2 G protein subunit that does not bind RGS protein are
resistance to diet-induced obesity [53]. However, the molecular
mechanism underlying the body-weight phenotype of these mice is
also likely to be different from that in the RGS9 knockout mice:
Gai2, is expressed ubiquitously in peripheral tissues and in many
brain regions and does not have the restricted expression pattern
of the RGS9 gene products [53].
Previously, altered RGS9-2 levels have been shown to be
involved in drug-addiction and the reward response to psycho-
stimulants [15] and our results are significant because we implicate
the same molecule in the control of body weight and adiposity.
Materials and Methods
Human genotyping
The human genotyping study was approved by the Human
Research Protection Program Committee on Human Research of
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was titled, ‘‘Discovery of Gene Mutations and Polymorphisms that
Contribute to the Risk of Cardiovascular and Metabolic Disease
and Macular Degeneration’’. The Institutional Review Board
number was 10–00207 and the permit number was 016323.
Written informed consent was obtained from all subjects.
DNA samples were analyzed for the presence of the DTTTCT
polymorphism from participants of East Asian ancestry, in the
University of California, San Francisco, Genomic Resource in
Arteriosclerosis (GRA) collection, which has been previously
described [54,55] and contains associated height, weight, sex
and age data. The body mass index for each subject was calculated
using the formula: mass (kg) 4 (height (m))
2 [25].
The primer sequences used for detecting the DTTTCT deletion
polymorphism were, forward, 59-GTGCAATAGCTTGTTCTG-
CG and reverse, 59-TGGCAAGTACAGTGAACTGATG (chr17:
63,197,962–63,198,341). Forward primers were fluorescently
labeled with 6-FAM (Life Technologies-Invitrogen-Applied Biosys-
tems, Carlsbad, CA). PCR was carried out using Platinum Taq
polymerase (Invitrogen). The PCR reaction was performed on 10 to
25 ng of genomic DNA with 2.0 mM MgCl2, 0.25 units Taq,
200 mM dNTPs, 0.02 mM of each primer and PCR buffer supplied
with the Taq enzyme. An ABI 3730 (Applied Biosystems) DNA
analyzer was utilized for the initial Sanger sequencing visualization
and fragment separation. The genotyping results were determined
by visualization using STRand [56] while Sequencher (Gene Codes
Corporation, Ann Arbor, MI) was used to analyze the sequencing
results.
The statistical analysis of the human data was performed using
IBM SPSS Statistics (IBM, Armonk, NY) and Systat 12 (Systat
Software, Chicago, IL) software.
Splicing reporter minigene assay
The reporter system used to screen for the possible effect on
splicing of the DTTTCT deletion polymorphism was derived from a
plasmid vector containing a 3 exon minigene under the control of
the human cytomegalovirus promoter and has previously been
described by Wang and colleagues [57]. The first and last exons of
the original 3 exon minigene consist of sequences that encode for
portions of the enhanced green fluorescent protein (eGFP). These
two exons are separated by a small constitutively spliced exon, of
the Chinese hamster dihydrofolate reductase (DHFR) gene,
together with its flanking introns. The DHFR exon also contains
two restriction cloning sites, Xho1 and Apa1, into which we
inserted a synthesized (Epoch Life Sciences, Missouri City, TX)
fragment of the human RGS9 gene [17]. A schematic of the
minigene construct is shown in Fig. 1A. The inserted RGS9 gene
fragment consisted of the final 57 base pairs of exon 13 (Fig. 1A,
grey box,) followed by a fusion of the first 100 and the last 243 base
pairs in the adjacent intron 13 (Fig. 1A, dashed grey bar). The
insertion of the regions from intron 13 of the RGS9 gene
effectively splits the central DHFR exon of the original minigene
into 2 separate exons thus creating a new minigene construct with
4 exons (Fig. 1A). To investigate the putative effect of the DTTTCT
deletion on splicing, a second construct, identical to the one
described above, was made except that the inserted RGS9 gene
fragment was synthesized with DTTTCT deletion (represented as D
in Fig. 1A) at the appropriate intron 13 site. To increase the
likelihood of detecting splicing effects of a polymorphism located
outside the canonical splicing sites, we weakened the canonical
splicing machinery near the 39 splicing site (CRA, at position -3)
and near the 59 splicing site (GRT, last position in the exon). A
similar strategy of weakening splicing signals or adding negative
elements to impair the recognition of a test exon has been
commonly used to test the effects of silencer or enhancer elements
in other studies [21].
Human embryonic kidney cells (HEK293, American Type
Culture Collection, Manassas, VA) were separately transfected
with equal amounts of the DTTTCT deletion positive (+ve) or the
DTTTCT deletion negative (-ve) minigene constructs described
above. The transient transfections were performed using LTX
transfection reagent (according to manufacturer’s instructions
Invitrogen, Carlsbad, CA).
After 48 hr the cells were harvested and total cellular RNA was
isolated using TRIzol reagent (according to manufacturer’s
instructions, Invitrogen). Next, the RNA was reverse transcribed
(reverse transcriptase enzyme, Sigma Aldrich) at 37 uC for 50 min
in a reaction that was primed with random hexamer nucleotides
and contained dNTP mixture and RNase inhibitor (Ambion) and
buffer provided by the enzyme supplier.
The resulting cDNA was amplified in a PCR reactions (25
cycles) using Taq DNA polymerase (Promega, Madison, WI) and
forward (59 AAATGGAATCCATCCCGG 39) and reverse (59
AAACCCTAGAATCCTCATC 39) primers flanking the first and
last exon of the minigene such that splicing alterations resulting
from exon skipping or intron retention would alter the size of the
PCR fragment amplified. The identity of the alternatively spliced
gene fragments were confirmed by sequencing.
Rodent studies
Rodent studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
experimental protocols using rats and mice were approved by the
Institutional Animal Care and Use Committee of the University of
Texas Southwestern Medical Center at Dallas or the University of
Rhode Island with protocol numbers, 0930-04-02-1 and 242945-
1, respectively.
Mouse Weight Measurements
Genotyping of the rgs9-/- mice was described previously [58].
Mice were backcrossed to C57BL/6J mice (Stock Number:
000664, Jackson Laboratory, Bar Harbor, ME) for four
generations. An rgs9+/- X rgs9+/- breeding strategy was used
to generate wild-type (rgs9+/+), heterozygous (rgs9+/-)a n d
RGS9 knockout (rgs9-/-) littermates. At weaning, mice were
tail-clipped for genotyping, ear-tagged, re-caged 4 per cage, in
polysulfone cages that were not environmentally enriched (part
#: RC71D-UD UdelH Polysulfone, Alternative Design, Siloam
Springs, AR, 18.4 cm wide, 29.2 cm deep, 12.7 cm high,
419.35 cm
2 floor area), with same sex, and switched from an
ad libitum 6% fat, breeding diet (catalog #: 7002, Teklad 6% Fat
Mouse/Rat Diet, Harlan, Indianapolis, IN) to an ad libitum 4%
fat standard laboratory chow diet (catalog #: 7002, Teklad 4%
Fat Mouse/Rat Diet, Harlan) and weighed daily until post-
weaning day 50.
Mouse Locomotor Activity Measurements
Locomotor activity was measured using an automated system
(Med Associates, St. Albans, VT). Mice were placed singly in
plastic activity chambers (12618633 cm) with 10 pairs of
photocell beams dividing the chamber into 10 rectangular fields
for measurement of total beam breaks, as described previously
[7]. 8 week old mice were placed into the cages and their
ambulatory locomotor activity was monitored for 2 hrs. Data
are presented as number of beam brakes after 30 min and after
2h r .
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Adipose Tissue
Epididymal, mesenteric and peri-renal adipose tissue depots
were excised from age-matched 2–3.5 month old male rgs9+/+
and rgs9-/- mice, fixed in 10% (vol/vol) buffered formalin and
then separately weighed. The mass of peri-renal adipose tissue
obtained from each mouse was too small to be accurately weighed
and therefore the peri-renal depot was not used in the subsequent
analyses.
For histological studies of the adipose tissues, the formalin fixed
tissues were dehydrated through graded ethanols, and embedded
in paraffin. Sections were cut at 4 mm and stained with
hematoxylin and eosin according to standard staining protocols
[59].
Bright field images of hemotoxylin and eosin stained sections
of mouse fat pads were captured using a 40X objective and
Nikon (Melville, NY) Eclipse TS100 microscope. The adipocyte
images were analyzed using the automated object/cell count-
ing and analysis features of NIS-Elements software (Nikon).
The software parameters were manually adjusted to maxi-
mize the detection and outlining of adipocytes borders in each
image. Misidentified cells and partial cell images at the edges at
the edges of each picture were manually excluded prior to
analysis.
Western blotting
Epididymal fat pads and striatal tissue was dissected from wild-
type (RGS9+/+) mice and Dounce homogenized in 1X phosphate
buffered saline (PBS) containing a cocktail of protease inhibitors
(catalog #: S8830, Sigma-Aldrich, St. Louis, MO), solubilized in
PBS containing 2% w/v sodium dodecyl sulfate (SDS) and
sonicated to reduce sample viscosity. Protein concentration of
resulting samples was determined using a BCA protein assay kit
(catalog #: IJ116707, Pierce/Thermo Scientific, Rockford, IL).
60 mg of total protein, diluted in SDS-sample buffer containing
2% SDS, 100 mM Tris-HCl, and 50 mM dithiothreitol (DTT)
was loaded per well of a 10-well mini-gel plate (mini-PROTEAN
1-dimensional electrophoresis system, Bio-Rad, Hercules, CA),
resolved by SDS-polyacrylamide gel electrophoresis (PAGE),
transferred to polyvinylidene fluoride (PVDF) membrane and
probed using a previously validated primary polyclonal sheep
antibody that specifically recognizes both long and short RGS9
isoforms [23] and an anti-sheep horse-radish peroxidase (HRP)-
conjugated secondary (Jackson ImmunoResearch, West Grove,
PA). A luminescent signal from the HRP-conjugated secondary
was elicited using a chemiluminescent HRP substrate (catalog #:
34096, Thermo Scientific) and visualized using the Gel-Doc
imaging system (Bio-Rad).
Herpes simplex virus (HSV) constructs.
The HSV vector used for overexpressing mouse RGS9-2
(Genbank accession number: AF125046) has been previously
described and validated [7,24]. The description of the control
HSV-LacZ (b-galactosidase) vector is provided elsewhere [60].
After cloning, HSV constructs were grown and purified
according to previously published protocols [61,62].
Rat Nucleus Accumbens (NAc) Protein Overexpression
All surgery was performed under anesthetic procedures
described below, and all efforts were made to minimize suffering.
Rat experiments were performed using one or more sets of 12
male Sprague-Dawley rats (250–275 gm, Charles River, Raleigh,
NC): 6 rats were injected with Herpes simplex virus (HSV)
transducing an RGS protein construct, while the remaining 6
control rats were injected with HSV transducing LacZ. Since
RGS9-2 is thought to be a specific modulator of striatal D2-
dopamine receptors (D2R) we attempted to balance the groups for
inter-individual differences in mesostriatal dopaminergic tone, by
measuring the levels of cocaine-induced locomotor activity.
Cocaine administration elevates extracellular dopamine levels in
the nucleus accumbens (NAc) [63], resulting in activation of
striatal dopamine receptors [64] and consequent behavioral
responses such as enhanced locomotion [65]. Thus the cocaine-
induced locomotor response was used as a surrogate measure to
balance inter-individual differences in striatal dopamine receptor
function and consequently enhance our ability to detect statisti-
cally significant weight alterations produced during the short 3–4
day window of HSV-induced protein expression [7]. The
balancing procedure was as follows: Following a 1 week
habituation to the vivarium, rats were tested for locomotor
responses to 10 mg/kg cocaine in an automated, infrared beam-
based locomotor activity recording chamber and were assigned to
either the experimental (HSV-RGS) or control (HSV-LacZ)
groups, so that the groups were roughly balanced for the
cocaine-induced locomotor activity.
The following day, rats were anesthetized (ketamine hydrochlo-
ride, 100 mg/kg and sodium pentobarbital, 30 mg/kg, i.p.) and
stereotaxically injected with 2 mL of either control LacZ virus or
the RGS protein transducing virus [62] bilaterally into the NAc
shell using a 26 gauge Hamilton syringe, arm mounted at 10u to
vertical, at A–P=+1.9, M–L=62.4 and D–V=26.7 relative to
bregma [66]. Expression of the HSV-delivered transgenes is
detected within 24 hr post injection, reaches a maximum between
days 4 and 5 and then rapidly ceases after day 6 [61,67]. After
recovery, rats continued to be fed ad libitum on a 4% fat rodent diet
(Harlan). On days 1-5 post-HSV injection, rats were weighed
between 5 and 7 hr after lights-on. At the end of the experiments,
rats were perfusion-fixed and syringe tip placement in the NAc
shell confirmed by histological analysis of Nissl-stained sections
through the NAc. Data from animals with injection placements
outside of the NAc shell were excluded from analysis (,8% of the
injected animals). The above experiment was repeated with each
construct at least 3 times.
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